AGC to acquire Boehringer Ingelheim’s API manufacturing plant in Spain
AGC, a Tokyo-headquartered manufacturer of glass, chemicals, and specialty materials, has agreed to acquire Boehringer Ingelheim’s Malgrat Pharma Chemicals (MPC), a subsidiary of BI in Spain that manufactures intermediates and active pharmaceutical ingredients (APIs). By acquiring MPC, AGC will have its first US FDA-registered site in Europe for its contract development and manufacturing (CDMO) business.
The deal remains subject to approval from the relevant antitrust authorities and the fulfillment of closing conditions under the share purchase agreement.
MPC has experience manufacturing cGMP-compliant commercial products as well as compounds in clinical development on a range of scales. Using AGC’s fluorination technologies and experience in its in-house drug discovery and its CDMO business built up in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services from a broader asset base, expanding its presence in the European market.